Gain Therapeutics disclosed a drug discovered through an AI plus physics‑based modeling platform that allosterically binds a dysfunctional enzyme, restores its function, and reduces neuroinflammation in preclinical models of Parkinson’s disease. The company’s executive, Gene Mack, presented the candidate as an example of computationally driven target engagement leading to a translational therapeutic. Gain’s approach highlights integration of structure‑based modeling with machine learning to prioritize molecules with an allosteric mechanism; next steps include IND‑enabling studies and early clinical testing to assess tolerability and biomarker effects on neuroinflammation.